Cargando…
Overweight and obesity are not associated with worse clinical outcomes in COVID-19 patients treated with fixed-dose 6 mg dexamethasone
OBJECTIVE: A fixed 6 mg dexamethasone dose for 10 days is the standard treatment for all hospitalised COVID-19 patients who require supplemental oxygen. Yet, the pharmacokinetic properties of dexamethasone can lead to diminishing systemic dexamethasone exposure with increasing body mass index (BMI)....
Autores principales: | Wittermans, Esther, Grutters, Jan C., Moeniralam, Hazra S., Ocak, Gurbey, Paul Voorn, G., Bos, Willem Jan W., van de Garde, Ewoudt M. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388353/ https://www.ncbi.nlm.nih.gov/pubmed/35982120 http://dx.doi.org/10.1038/s41366-022-01204-1 |
Ejemplares similares
-
Latent class analysis-based subgroups and response to corticosteroids in hospitalised community-acquired pneumonia patients: a validation study
por: Wittermans, Esther, et al.
Publicado: (2023) -
Inter-hospital variation in the utilization of diagnostics and their proportionality in the management of adult community-acquired pneumonia
por: Vestjens, Stefan M. T., et al.
Publicado: (2018) -
Community-acquired pneumonia subgroups and differential response to corticosteroids: a secondary analysis of controlled studies
por: Wittermans, Esther, et al.
Publicado: (2022) -
Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis
por: Spoorenberg, Simone MC, et al.
Publicado: (2014) -
Migration background and COVID-19 related intensive care unit admission and mortality in the Netherlands: A cohort study
por: Ocak, Gurbey, et al.
Publicado: (2023)